Lange M, Hardy-Léger I, Licaj I, et al. - Since 20% to 30% of patients with breast cancer had cognitive impairment following surgery but prior to adjuvant treatment but little is known about cognition before treatment, researchers used a subgroup of women from the French cancer and toxicities (CANTO) cohort with newly diagnosed breast cancer to characterize cognition before any treatment vs a group of healthy controls (HC). Cognitive testing was conducted prior to any breast cancer treatment (surgery or neoadjuvant treatment) on women with newly diagnosed invasive stage I–III breast cancer and on HCs. Of the 264 breast cancer patients (54 ± 11 years), overall objective cognitive impairment was observed in 28%; out of 132 age-matched HCs (53 ± 9 years), overall objective cognitive impairment was observed in 8%. Researchers reported that 24% of patients with breast cancer vs 12% of HCs reported cognitive complaints. Compared to HCs, breast cancer patients expressed much more anxiety and emotional and cognitive fatigue. Cognitive complaints were positively linked to fatigue. According to this prospective study, patients with localized breast cancer had more objective cognitive impairment before any treatment vs HCs.